North America and Europe PEGylated Drugs Market Size By Disease Indication (Cancer, Hepatitis, Multiple Sclerosis, Gastrointestinal Disorders), By Type (Monoclonal Antibodies, Colony Stimulating Factors, Interferons), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2024

Published Date: Apr 2018  |  Report ID: GMI2511  |  Authors: Sumant Ugalmugale

Report Format: PDF   |   Pages: 100   |   Base Year: 2017




Summary Table of Contents Industry Coverage Methodology

Report Content

Chapter 1.  Methodology

1.1. Methodology

1.1.1.  Methodology

1.1.2.  Market definition

1.1.3.  Forecast parameters

1.1.4.  Data sources

1.1.4.1.    Primary

1.1.4.2.    Secondary

Chapter 2.  Executive Summary

2.1. North America & Europe PEGylated drugs industry 3600 synopsis, 2013 - 2024 (USD Million)

2.1.1.  Business trends

2.1.2.  Disease indication trends

2.1.3.  Type trends

2.1.4.  Regional trends

Chapter 3.  North America & Europe PEGylated Drugs Industry Insights

3.1. Industry segmentation

3.2. Industry impact forces

3.2.1.  Growth drivers

3.2.1.1.    Increasing prevalence of cancer in developed regions

3.2.1.2.    Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe

3.2.1.3.    Growing biologics sector in the developed economies

3.2.2.  Industry pitfalls & challenges

3.2.2.1.    Drug recalls in the U.S. & Europe

3.2.2.2.    Adverse drug reactions

3.3. Growth potential analysis

3.3.1.  By disease indication

3.3.2.  By type

3.4. Regulatory landscape

3.4.1.  U.S.

3.4.2.  Europe

3.5. Porter's analysis

3.6. Pipeline analysis

3.7. Competitive landscape, 2017

3.7.1.  Strategy dashboard

3.8. PESTEL analysis

Chapter 4.  North America & Europe PEGylated Drugs Market, By Disease Indication

4.1. North America & Europe PEGylated drugs market share by disease indication, 2017 & 2024 

4.2. Cancer

4.2.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

4.3. Hepatitis 

4.3.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.4. Multiple sclerosis

4.4.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.5. Gastrointestinal disorders

4.5.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.6. Others

4.6.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

Chapter 5.  North America & Europe PEGylated Drugs, By Type

5.1. North America & Europe PEGylated drugs market share by type, 2017 & 2024 

5.2. Monoclonal antibodies (mAbs)

5.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.3. Colony stimulating factors

5.3.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.4. Interferons

5.4.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.5. Others

5.5.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

Chapter 6.  North America & Europe PEGylated Drugs Market, By Country

6.1. North America & Europe PEGylated drugs market share by country, 2017 & 2024 

6.2. North America

6.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

6.2.2.  Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.3.  Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.2.4.  U.S.

6.2.4.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.4.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.2.5. Canada

6.2.5.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.2.5.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3. Europe

6.3.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

6.3.2.  Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.3.  Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.4.  Germany

6.3.4.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.4.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.5. France

6.3.5.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.5.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.6. UK

6.3.6.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.6.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

6.3.7. Spain

6.3.7.1.    Market estimates and forecast, by disease indication, 2013 - 2024 (USD Million)

6.3.7.2.    Market estimates and forecast, by type, 2013 - 2024 (USD Million)

Chapter 7.  Company Profiles

7.1. Merck KGaA

7.1.1.  Business overview

7.1.2.  Financial data

7.1.3.  Product landscape

7.1.4.  Strategic outlook

7.1.5.  SWOT analysis

7.2. Biogen Inc.

7.2.1.  Business overview

7.2.2.  Financial data

7.2.3.  Product landscape

7.2.4.  Strategic outlook

7.2.5.  SWOT analysis

7.3. AstraZeneca

7.3.1.  Business overview

7.3.2.  Financial data

7.3.3.  Product landscape

7.3.4.  Strategic outlook

7.3.5.  SWOT analysis

7.4. UCB

7.4.1.  Business overview

7.4.2.  Financial data

7.4.3.  Product landscape

7.4.4.  Strategic outlook

7.4.5.  SWOT analysis

7.5. Amgen

7.5.1.  Business overview

7.5.2.  Financial data

7.5.3.  Product landscape

7.5.4.  Strategic outlook

7.5.5.  SWOT analysis

7.6. Sigma Tau (Leadiant Biosciences)

7.6.1.  Business overview

7.6.2.  Financial data

7.6.3.  Product landscape

7.6.4.  Strategic outlook

7.6.5.  SWOT analysis

7.7. Roche

7.7.1.  Business overview

7.7.2.  Financial data

7.7.3.  Product landscape

7.7.4.  Strategic outlook

7.7.5.  SWOT analysis

7.8. Shire Group

7.8.1.   Business overview

7.8.2.   Financial data

7.8.3.   Product landscape

7.8.4.   Strategic outlook

7.8.5.   SWOT analysis

7.9. Pfizer

7.9.1.   Business overview

7.9.2.   Financial data

7.9.3.   Product landscape

7.9.4.   Strategic outlook

7.9.5.   SWOT analysis

7.10. Novo Nordisk

7.10.1. Business overview

7.10.2. Financial data

7.10.3. Product landscape

7.10.4. Strategic outlook

7.10.5. SWOT analysis

 

 

 

Data Tables

TABLE 1.    North America & Europe PEGylated drugs industry 3600 synopsis, 2013 – 2024

TABLE 2.    Industry impact forces

TABLE 3.    Cancer market size, by country, 2013 - 2024

TABLE 4.    Hepatitis market size, by country, 2013 - 2024

TABLE 5.    Multiple sclerosis market size, by country, 2013 - 2024

TABLE 6.    Gastrointestinal disorders market size, by country, 2013 - 2024

TABLE 7.    Others market size, by country, 2013 - 2024

TABLE 8.    Monoclonal antibodies (mAbs) market size, by country, 2013 - 2024

TABLE 9.    Colony stimulating factors market size, by country, 2013 - 2024

TABLE 10.    Interferons market size, by country, 2013 - 2024

TABLE 11.    Others market size, by country, 2013 - 2024

TABLE 12.    North America PEGylated drugs market, by country 2013 - 2024    

TABLE 13.    North America PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 14.    North America PEGylated drugs market, by type, 2013 - 2024

TABLE 15.    U.S PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 16.    U.S. PEGylated drugs market, by type, 2013 - 2024

TABLE 17.    Canada PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 18.    Canada PEGylated drugs market, by type, 2013 - 2024

TABLE 19.    Europe PEGylated drugs market, by country 2013 - 2024    

TABLE 20.    Europe PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 21.    Europe PEGylated drugs market, by type, 2013 - 2024

TABLE 22.    Germany PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 23.    Germany PEGylated drugs market, by type, 2013 - 2024

TABLE 24.    UK PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 25.    UK PEGylated drugs market, by type, 2013 - 2024

TABLE 26.    France PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 27.    France PEGylated drugs market, by type, 2013 - 2024

TABLE 28.    Spain PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 29.    Spain PEGylated drugs market, by type, 2013 - 2024

TABLE 30.    Italy PEGylated drugs market, by disease indication, 2013 - 2024

TABLE 31.    Italy PEGylated drugs market, by disease indication, 2013 - 2024
 

Charts & Figures

FIG. 1    Industry segmentation

FIG. 2    Growth potential analysis

FIG. 3    Porter’s analysis

FIG. 4    PESTEL analysis

FIG. 5    Strategy dashboard

FIG. 6    North America & Europe PEGylated drugs market share, by disease indication, 2017 & 2024

FIG. 7    North America & Europe PEGylated drugs market share, by type, 2017 & 2024

FIG. 8    North America & Europe PEGylated drugs market share, by country, 2017 & 2024

 

Buy Now

Single User: $3,550 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $5,550 Access for 2 to 5 users only within same department of one company
Enterprise User: $7,550 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Why Global Market Insights, Inc.?

Reliability & accuracy

  • GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.

Quality & trust


  • BBB Rating - Click to Verify

Customer service

  • Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.

Security & compliance

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X